1.Highly active antiretroviral therapy on liver function in HIV-positive children with HBV/HCV co-infection.
Li-juan WU ; Chang-zhong JIN ; Shi BAI ; Yong LIANG ; Nan-ping WU
Journal of Zhejiang University. Medical sciences 2014;43(2):180-186
OBJECTIVETo assess changes of liver function in HIV-positive children with/without HBV/ HCV co-infection after 1 year of highly active antiretroviral therapy (HARRT).
METHODSSeventy-eight pediatric AIDS patients with HBV/HCV co-infection,19 pediatric AIDS patients with HBV co-infection and 44 pediatric AIDS patients without HBV/HCV co-infection who received HAART at least for 1 year were enrolled. HIV-1 viral load was quantitatively detected using a standardized reverse transcriptase-polymerase chain reaction assay, and blood cells were determined by three-color flow cytometry. Anti-HCV antibody and HBsAg was detected using an enzyme-linked immunosorbent technique, and ALT, AST and TBIL were detected by automatic biochemical analyzer.
RESULTSAfter 1 year-HAART, the viral load was decreased to the lowest limit of detection in 90.34% patients (t=2.61, P<0.01), and CD4+ T cell counts were increased from 170.187±132.405/ μl to 796.014±158.491/ μl (t=3.17, P<0.01). The levels of ALT and AST were elevated (t=2.02, P<0.05), while the ALT and AST levels in patients receiving nevirapine (NVP) based HAART increased from 18.28±13.74 U/L and 24.23±8.09 U/L to 55.35±22.40 U/L and 69.97±26.72 U/L, respectively(t=3.80,t=4.11;Ps<0.01). The increment of ALT and AST in NVP based HAART were significantly higher than that in the efavirenz based HAART (ALT:46.28±13.35 U/L vs 37.70±15.25 U/L and AST:19.53±7.23 U/L vs 1.25±0.21 U/L, respectively; t=4.53, t=5.79; Ps<0.01), particularly in patients co-infected with HIV/HBV/HCV (ALT:54.32±22.85 U/L vs 16.89±14.42 U/L and AST:41.71±19.26 U/L vs -3.44±15.59 U/L, respectively; t=3.42, t=2.98, Ps<0.01).
CONCLUSIONHARRT can repress HIV-1 replication effectively, but it also cause the damage of liver function, especially in patients with HBV and/or HCV co-infection.
Antiretroviral Therapy, Highly Active ; Child ; Coinfection ; drug therapy ; Female ; HIV Infections ; complications ; drug therapy ; physiopathology ; Hepatitis B ; complications ; Hepatitis C ; complications ; Humans ; Liver ; physiopathology ; Male
2.Treatment of hepatitis B co-infected with HCV or HIV.
Chinese Journal of Hepatology 2010;18(7):491-494
4.Occult Hepatitis B Virus Infection in Chronic Hepatitis C.
The Korean Journal of Gastroenterology 2013;62(3):154-159
Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for HBsAg. Studies on occult HBV infection in hepatitis C patients have reported highly variable prevalence, because the prevalence of occult HBV infection varies depending on the hepatitis B risk factors and methodological approaches. The most reliable diagnostic approach for detecting occult HBV detection is through examination of liver DNA extracts. HCV has been suspected to strongly suppress HBV replication up to the point where it may be directly responsible for occult HBV infection development. However, more data are needed to arrive at a definitive conclusion regarding the role of HCV in inducing occult HBV infection. Occult HBV infection in chronic hepatitis C patients is a complex biological entity with possible relevant clinical implications. Influence of occult HBV infection on the clinical outcomes of chronic hepatitis C may be considered negative. However, recent studies have shown that occult HBV infection could be associated with the development of hepatocellular carcinoma and contribute to the worsening of the course of chronic liver disease over time in chronic hepatitis C patients. Nevertheless, the possible role of occult HBV infection in chronic hepatitis C is still unresolved and no firm conclusion has been made up until now. It still remains unclear how occult HBV infection affects the treatment of chronic hepatitis C. Therefore, in order to resolve current controversies and understand the pathogenic role and clinical impacts of occult HBV infection in chronic hepatitis C patients, well-designed clinical studies are needed.
Carcinoma, Hepatocellular/complications
;
DNA, Viral/analysis
;
Hepacivirus/genetics
;
Hepatitis B/*complications/*diagnosis/drug therapy
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/*complications/*diagnosis/drug therapy
;
Humans
;
Interferon-alpha/therapeutic use
;
Liver/virology
;
Liver Neoplasms/complications
7.A Case of Acute Disseminated Encephalomyelitis Associated with Hepatitis C Virus Infection.
Jae Eun SIM ; Jun Bum LEE ; Yu Na CHO ; Sang Hyun SUH ; Ja Kyung KIM ; Kyung Yul LEE
Yonsei Medical Journal 2012;53(4):856-858
Acute disseminated encephalomyelitis (ADEM) is a monophasic autoimmune demyelinating disease of the central nervous system, which typically follows acute viral or bacterial infection or vaccination. We report a case of ADEM associated with hepatitis C virus (HCV) infection with positive serum and cerebrospinal fluid (CSF) anti-HCV antibody. After steroid treatment, neurologic symptoms were improved. Virus triggers autoimmunity or direct viral invasion plays a part in the genesis of ADEM. This is the first reported case of ADEM with anti-HCV antibody in the CSF.
Encephalomyelitis, Acute Disseminated/*diagnosis/drug therapy/etiology/virology
;
Female
;
Hepacivirus/pathogenicity
;
Hepatitis C/*complications
;
Humans
;
Methylprednisolone/therapeutic use
;
Middle Aged
8.Clinical observation on effect of shennong xian'ganling capsule in treating chronic hepatitis and liver cirrhosis.
Chinese Journal of Integrated Traditional and Western Medicine 2004;24(5):450-452
Adolescent
;
Adult
;
Aged
;
Capsules
;
Drugs, Chinese Herbal
;
therapeutic use
;
Female
;
Hepatitis B, Chronic
;
complications
;
drug therapy
;
Hepatitis C, Chronic
;
complications
;
drug therapy
;
Humans
;
Liver Cirrhosis
;
drug therapy
;
etiology
;
Male
;
Middle Aged
;
Phytotherapy
9.Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization.
Pil Soo SUNG ; Si Hyun BAE ; Jeong Won JANG ; Do Seon SONG ; Hee Yeon KIM ; Sun Hong YOO ; Chung Hwa PARK ; Jung Hyun KWON ; Myeong Jun SONG ; Chan Ran YOU ; Jong Young CHOI ; Seung Kew YOON
The Korean Journal of Hepatology 2011;17(4):299-306
BACKGROUND/AIMS: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence of enhanced HCV replication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemolipiodolization (TACL) and to identify the factors associated with enhanced replication of HCV. The clinical pattern of enhanced HCV replication was compared with hepatitis B virus (HBV) reactivation during TACL. METHODS: This study enrolled 49 anti-HCV-seropositive patients who were diagnosed with HCC between January 2005 and December 2010 and who underwent TACL using epirubicin and/or cisplatin with consecutive HCV RNA copies checked. For comparison, 46 hepatitis B surface antigen1-positive patients with HCC who were treated with TACL were also enrolled. The frequency, associated factors, and clinical outcomes of enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL. RESULTS: Enhanced replication of HCV occurred in 13 (26.5%) of the 49 anti-HCV-seropositive patients during TACL. Of these 13 patients, 4 developed hepatitis, but none of the subjects developed decompensation due to the hepatitis. No significant clinical factors for enhanced HCV replication during TACL were found. Compared with HBV reactivation, the frequency of hepatitis attributed to enhanced HCV replication was significantly lower than that for HBV reactivation (8.2% vs. 23.9%, P=0.036). CONCLUSIONS: TACL can enhance HCV replication; however, the likelihood of hepatitis and decompensation stemming from enhanced HCV replication was lower than that for HBV reactivation in patients undergoing TACL.
Adult
;
Aged
;
Antineoplastic Agents/*administration & dosage/adverse effects/pharmacology
;
Carcinoma, Hepatocellular/complications/*therapy
;
Chemoembolization, Therapeutic/*adverse effects
;
Drug Therapy, Combination
;
Female
;
Hepacivirus/drug effects/*physiology
;
Hepatitis B/complications/epidemiology/virology
;
Hepatitis B Surface Antigens/blood
;
Hepatitis B virus/drug effects/*physiology
;
Hepatitis C/complications/epidemiology/virology
;
Humans
;
Liver Neoplasms/complications/*therapy
;
Male
;
Middle Aged
;
RNA, Viral/analysis
;
Retrospective Studies
;
Virus Activation
;
*Virus Replication
10.Life quality analysis of hepatitis C patients with liver cirrhosis undergoing antiviral therapy following splenectomy.
Guangxi JI ; Yonghong GUO ; Lin CHEN ; Ying ZHANG ; Yu HE ; Li MA ; Yu WANG ; Zhiyuan MA ; Cheng CHENG ; Zhansheng JIA
Chinese Journal of Hepatology 2014;22(3):195-199
OBJECTIVETo evaluate the effect of antiviral therapy on the quality of life (QOL) of patients with chronic hepatitis C (CHC) and cirrhosis during the 5-year period following splenectomy to treat hypersplenism.
METHODSData of patients with CHC and cirrhosis who had undergone treatment for hypersplenism were retrospectively selected from the hospital database of medical records. The patients were first grouped according to the hypersplenism treatment: splenectomy (group A, 28 cases) and conservative/non-operative (group B, 30 cases). Sub-grouping was carried out according to the CHC treatment: interferon-alpha-2a and ribavirin (15 cases in the A1 group, and 19 cases in the B1 group) and non-antiviral (13 cases in the A2 group, and 11 cases in the B2 group). To determine the intergroup differences in QOL during the 5-year period following the hypersplenism treatment, the QOL was assessed by chronic liver disease questionnaire (CLDQ), listing of specific symptoms (SS), and the World Health Organization QOL scale (WHOQOL-BREF).
RESULTSBetween-group statistical comparison of the subjective feeling, physiological status, mental state, and social life relationship of the patients showed no significant differences among the patients who received splenectomy compared to those who received the conservative treatment. However, the QOL of splenectomy-treated patients who received non-antiviral CHC treatment was worse than that of the patients who were given conservative treatment for the hypersplenism and antiviral therapy for the CHC. The patients who received splenectomy and antiviral therapy had better QOL than the other patient group(3.69 +/- 0.75 vs 2.15 +/- 0.98, P = 0.0003).
CONCLUSIONSplenectomy followed by antiviral therapy may improve the QOL of patients with CHC-related cirrhosis and hypersplenism.
Adult ; Antiviral Agents ; therapeutic use ; Female ; Hepatitis C, Chronic ; complications ; drug therapy ; Humans ; Liver Cirrhosis ; drug therapy ; virology ; Male ; Middle Aged ; Quality of Life ; Retrospective Studies ; Splenectomy ; Treatment Outcome